依拉瓦环素治疗肺移植受者耐碳青霉烯鲍曼不动杆菌:一项真实世界回顾性研究。

IF 2.9 3区 医学 Q2 INFECTIOUS DISEASES
Infection and Drug Resistance Pub Date : 2025-08-16 eCollection Date: 2025-01-01 DOI:10.2147/IDR.S529016
Juan Chen, Xingxian Qian, Bingqing Yue, Huiru Lin, Shuo Ding, Jingyu Chen, Man Huang
{"title":"依拉瓦环素治疗肺移植受者耐碳青霉烯鲍曼不动杆菌:一项真实世界回顾性研究。","authors":"Juan Chen, Xingxian Qian, Bingqing Yue, Huiru Lin, Shuo Ding, Jingyu Chen, Man Huang","doi":"10.2147/IDR.S529016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) infections were associated with higher mortality and significant healthcare burden. Novel antibiotics provided a powerful weapon against CRAB. This study aimed to describe the effectiveness of eravacycline for the treatment of CRAB infections in lung transplant recipients.</p><p><strong>Methods: </strong>This was a single-center, retrospective study that enrolled lung transplant recipients with CRAB infections who received eravacycline for over 72 hours between August 2023 and December 2024. The primary outcome was 28-day survival rate. Secondary outcomes included 14-day survival and clinical failure rate.</p><p><strong>Results: </strong>A total of 24 lung transplant recipients were enrolled, with a median age of 60.5 years and a predominance of male patients. Nearly half had interstitial lung disease as the primary pulmonary condition. These recipients in our study mainly had pulmonary infections attacked by CRAB, with six individuals suffering septic shock. The median duration of eravacycline therapy was 10 days, with most patients receiving combination therapy. The primary outcome, the 28-day survival rate, was 83.3%, while the secondary outcomes showed a 14-day survival rate of 100% and a clinical failure rate of 37.5%. The median ICU and hospital lengths of stay were 12.5 and 55 days, respectively. A comparison between patients with and without clinical failure showed that those with clinical failure were older, had a higher incidence of septic shock, a higher proportion of continuous renal replacement therapy, and a longer ICU stays. Additionally, these patients exhibited an elevated heart rate, higher levels of ALT and AST, lower protein levels (total protein, albumin), prolonged PT and APTT, and increased level of CRP and PCT at the end of treatment.</p><p><strong>Conclusion: </strong>This study presented the clinical efficacy of eravacycline in lung transplant recipients with CRAB infections, providing valuable evidence and clinical experience for its use in organ transplant populations.</p>","PeriodicalId":13577,"journal":{"name":"Infection and Drug Resistance","volume":"18 ","pages":"4125-4139"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367918/pdf/","citationCount":"0","resultStr":"{\"title\":\"Eravacycline Treatment for Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Lung Transplant Recipients: A Real-World Retrospective Study.\",\"authors\":\"Juan Chen, Xingxian Qian, Bingqing Yue, Huiru Lin, Shuo Ding, Jingyu Chen, Man Huang\",\"doi\":\"10.2147/IDR.S529016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) infections were associated with higher mortality and significant healthcare burden. Novel antibiotics provided a powerful weapon against CRAB. This study aimed to describe the effectiveness of eravacycline for the treatment of CRAB infections in lung transplant recipients.</p><p><strong>Methods: </strong>This was a single-center, retrospective study that enrolled lung transplant recipients with CRAB infections who received eravacycline for over 72 hours between August 2023 and December 2024. The primary outcome was 28-day survival rate. Secondary outcomes included 14-day survival and clinical failure rate.</p><p><strong>Results: </strong>A total of 24 lung transplant recipients were enrolled, with a median age of 60.5 years and a predominance of male patients. Nearly half had interstitial lung disease as the primary pulmonary condition. These recipients in our study mainly had pulmonary infections attacked by CRAB, with six individuals suffering septic shock. The median duration of eravacycline therapy was 10 days, with most patients receiving combination therapy. The primary outcome, the 28-day survival rate, was 83.3%, while the secondary outcomes showed a 14-day survival rate of 100% and a clinical failure rate of 37.5%. The median ICU and hospital lengths of stay were 12.5 and 55 days, respectively. A comparison between patients with and without clinical failure showed that those with clinical failure were older, had a higher incidence of septic shock, a higher proportion of continuous renal replacement therapy, and a longer ICU stays. Additionally, these patients exhibited an elevated heart rate, higher levels of ALT and AST, lower protein levels (total protein, albumin), prolonged PT and APTT, and increased level of CRP and PCT at the end of treatment.</p><p><strong>Conclusion: </strong>This study presented the clinical efficacy of eravacycline in lung transplant recipients with CRAB infections, providing valuable evidence and clinical experience for its use in organ transplant populations.</p>\",\"PeriodicalId\":13577,\"journal\":{\"name\":\"Infection and Drug Resistance\",\"volume\":\"18 \",\"pages\":\"4125-4139\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367918/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection and Drug Resistance\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/IDR.S529016\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Drug Resistance","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IDR.S529016","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:耐碳青霉烯鲍曼不动杆菌(CRAB)感染与较高的死亡率和显著的医疗负担相关。新型抗生素为抗击螃蟹提供了有力的武器。本研究旨在描述依瓦环素治疗肺移植受者CRAB感染的有效性。方法:这是一项单中心回顾性研究,纳入了2023年8月至2024年12月期间接受依瓦环素治疗超过72小时的螃蟹感染肺移植受体。主要终点为28天生存率。次要结局包括14天生存率和临床失败率。结果:共纳入24例肺移植受者,中位年龄60.5岁,以男性患者为主。近一半的患者原发肺部疾病为间质性肺疾病。在我们的研究中,这些接受者主要是肺部感染的螃蟹,有6人发生感染性休克。依拉瓦环素治疗的中位持续时间为10天,大多数患者接受联合治疗。主要终点28天生存率为83.3%,次要终点14天生存率为100%,临床失败率为37.5%。ICU和住院时间的中位数分别为12.5天和55天。临床失败患者与非临床失败患者的比较显示,临床失败患者年龄较大,脓毒性休克发生率较高,持续肾替代治疗比例较高,ICU住院时间较长。此外,这些患者在治疗结束时表现出心率升高,ALT和AST水平升高,蛋白质水平(总蛋白,白蛋白)降低,PT和APTT延长,CRP和PCT水平升高。结论:本研究展示了依拉瓦环素治疗肺移植受者并发CRAB感染的临床疗效,为其在器官移植人群中的应用提供了有价值的依据和临床经验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Eravacycline Treatment for Carbapenem-Resistant Acinetobacter baumannii in Lung Transplant Recipients: A Real-World Retrospective Study.

Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) infections were associated with higher mortality and significant healthcare burden. Novel antibiotics provided a powerful weapon against CRAB. This study aimed to describe the effectiveness of eravacycline for the treatment of CRAB infections in lung transplant recipients.

Methods: This was a single-center, retrospective study that enrolled lung transplant recipients with CRAB infections who received eravacycline for over 72 hours between August 2023 and December 2024. The primary outcome was 28-day survival rate. Secondary outcomes included 14-day survival and clinical failure rate.

Results: A total of 24 lung transplant recipients were enrolled, with a median age of 60.5 years and a predominance of male patients. Nearly half had interstitial lung disease as the primary pulmonary condition. These recipients in our study mainly had pulmonary infections attacked by CRAB, with six individuals suffering septic shock. The median duration of eravacycline therapy was 10 days, with most patients receiving combination therapy. The primary outcome, the 28-day survival rate, was 83.3%, while the secondary outcomes showed a 14-day survival rate of 100% and a clinical failure rate of 37.5%. The median ICU and hospital lengths of stay were 12.5 and 55 days, respectively. A comparison between patients with and without clinical failure showed that those with clinical failure were older, had a higher incidence of septic shock, a higher proportion of continuous renal replacement therapy, and a longer ICU stays. Additionally, these patients exhibited an elevated heart rate, higher levels of ALT and AST, lower protein levels (total protein, albumin), prolonged PT and APTT, and increased level of CRP and PCT at the end of treatment.

Conclusion: This study presented the clinical efficacy of eravacycline in lung transplant recipients with CRAB infections, providing valuable evidence and clinical experience for its use in organ transplant populations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Infection and Drug Resistance
Infection and Drug Resistance Medicine-Pharmacology (medical)
CiteScore
5.60
自引率
7.70%
发文量
826
审稿时长
16 weeks
期刊介绍: About Journal Editors Peer Reviewers Articles Article Publishing Charges Aims and Scope Call For Papers ISSN: 1178-6973 Editor-in-Chief: Professor Suresh Antony An international, peer-reviewed, open access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventative strategies to minimize the development and spread of resistance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信